Scarica l'app Stockscreener
167.50
1.58%
2.61
Precedente Chiudi:
$164.89
Aprire:
$164.89
Volume 24 ore:
606.10K
Relative Volume:
0.61
Capitalizzazione di mercato:
$10.18B
Reddito:
$4.09B
Utile/perdita netta:
$-404.84M
Rapporto P/E:
-24.83
EPS:
-6.7469
Flusso di cassa netto:
$1.24B
1 W Prestazione:
-1.30%
1M Prestazione:
+22.52%
6M Prestazione:
+51.87%
1 anno Prestazione:
+35.52%
Intervallo 1D:
$163.77
$168.30
Intervallo di 1 settimana:
$161.00
$170.87
Portata 52W:
$95.49
$182.99
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Confronta JAZZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
167.50 | 10.02B | 4.09B | -404.84M | 1.24B | -6.7469 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Downgrade | UBS | Buy → Neutral |
| 2025-07-15 | Iniziato | Deutsche Bank | Buy |
| 2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
AQR Arbitrage LLC Sells 9,118 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Mary Elizabeth Henderson Sells 2,238 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Holdings Lowered by California Public Employees Retirement System - MarketBeat
Jazz Pharmaceuticals Insider Sold Shares Worth $379,366, According to a Recent SEC Filing - marketscreener.com
Guggenheim Capital LLC Sells 11,619 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Piper Sandler Raises Price Target for Jazz Pharmaceuticals (JAZZ) to $219 | JAZZ Stock News - GuruFocus
Piper Sandler raises Jazz Pharmaceuticals stock price target to $219 on positive trial results - Investing.com Nigeria
Carr Patricia, SVP at Jazz Pharma, sells $797k in JAZZ stock - Investing.com India
Jazz Pharmaceuticals Insider Sold Shares Worth $797,783, According to a Recent SEC Filing - marketscreener.com
Jazz Pharmaceuticals (Nasdaq: JAZZ) shares Phase 4 DUET Xywav data in narcolepsy, IH - Stock Titan
Kennedy Capital Management LLC Buys Shares of 10,367 Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals Plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking After Shares Rocket 29% - 富途牛牛
Schroder Investment Management Group Acquires 8,444 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Why Analysts Think Jazz Pharmaceuticals Story Is Changing After New Ziihera Growth Outlook - Yahoo Finance
Jazz Pharmaceuticals to present new Epidiolex data at epilepsy meeting By Investing.com - Investing.com Nigeria
Affinity Asset Advisors LLC Makes New $2.65 Million Investment in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Do New Epidiolex Real‑World Data Reframe Jazz Pharmaceuticals' (JAZZ) Neurology Growth Ambitions? - simplywall.st
VP Carr Files To Sell 4,660 Of Jazz Pharmaceuticals Plc [JAZZ] - TradingView
Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue? - sharewise.com
Jazz Pharmaceuticals plc to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex®? (Cannabidiol) Outcomes in Treatment-Resistant Epilepsies At the American Epilepsy Society 2025 Annual Meeting - marketscreener.com
Jazz Pharmaceuticals to present new Epidiolex data at epilepsy meeting - Investing.com
Jazz Pharmaceuticals (Nasdaq: JAZZ) unveils EpiCom and real-world Epidiolex findings at AES 2025 - Stock Titan
Saturn V Capital Management LP Buys New Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Trials, Sales Wins Sends Jazz Pharmaceuticals Higher - Yahoo Finance
Dir O'Keefe Surrenders 603 Of Jazz Pharmaceuticals Plc [JAZZ] - TradingView
Will Jazz Pharmaceuticals plc stock pay special dividendsEarnings Beat & High Conviction Buy Zone Picks - Newser
Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Systematic Financial Management LP - MarketBeat
Is Jazz Pharmaceuticals plc (J7Z) stock attractive for growth fundsEarnings Summary Report & Real-Time Buy Signal Alerts - Newser
Why hedge funds are buying Jazz Pharmaceuticals plc stock2025 Volume Leaders & Low Drawdown Momentum Trade Ideas - Newser
What MACD trends signal for Jazz Pharmaceuticals plc (J7Z) stockPortfolio Profit Report & Expert Verified Movement Alerts - Newser
How Jazz Pharmaceuticals plc (J7Z) stock performs in easing cyclesShort Setup & Weekly Market Pulse Updates - Newser
Mackenzie Financial Corp Raises Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Bought by Prudential Financial Inc. - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Distillate Capital Partners LLC - MarketBeat
Will Jazz Pharmaceuticals plc (J7Z) stock benefit from infrastructure billQuarterly Performance Summary & Fast Moving Market Watchlists - Newser
Will Jazz Pharmaceuticals plc (J7Z) stock outperform benchmarksQuarterly Risk Review & Expert Verified Movement Alerts - Newser
Why Jazz Pharmaceuticals plc (J7Z) stock appeals to dividend investorsPrice Action & AI Driven Stock Movement Reports - Newser
Does Jazz Pharmaceutical's Acquisition of Gentium S.p.A. Signal Investment Upside? - AOL.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $13,780,275.00 in Stock - MarketBeat
Jazz to present pivotal phase 3 results for Ziihera in GEA at ASCO GI - Investing.com Canada
Jazz Pharmaceuticals (Nasdaq: JAZZ) to present Ziihera Phase 3 GEA data at ASCO GI - Stock Titan
Looking Into Jazz Pharmaceuticals PLC's Recent Short Interest - Benzinga
Capital Fund Management S.A. Takes $4.27 Million Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Loomis Sayles & Co. L P Trims Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Is Jazz Pharmaceuticals plc stock attractive for retirement portfoliosJuly 2025 Recap & Reliable Entry Point Trade Alerts - Newser
Why Jazz Pharmaceuticals plc (J7Z) stock remains stableJuly 2025 Momentum & Fast Gain Swing Alerts - Newser
Jazz Pharmaceuticals Insider Sold Shares Worth $13,780,337, According to a Recent SEC Filing - marketscreener.com
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium - PR Newswire
Dir O'Keefe Files To Sell 1,249 Of Jazz Pharmaceuticals Plc [JAZZ] - TradingView
Jazz Pharmaceuticals Director Bruce C. Cozadd Sells 77,500 Shares - TradingView
Chmn Cozadd Sells 77,500 ($13.8M) Of Jazz Pharmaceuticals Plc [JAZZ] - TradingView
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):